Determination of docetaxel in dried blood spots by LC-MS/MS: Method development, validation and clinical application

被引:18
作者
Raymundo, S. [1 ,2 ]
Muller, V. V. [2 ]
Andriguetti, N. B. [1 ,2 ]
Tegner, M. [1 ]
Artmann, A. C. [1 ]
Kluck, H. M. [3 ]
Franzoi, M. A. [3 ]
Vilela, R. M. M. [4 ]
Schwartsmann, G. [3 ]
Linden, R. [1 ,2 ]
Antunes, M. V. [1 ,2 ]
机构
[1] Univ Feevale, Grad Program Toxicol & Analyt Toxicol, Novo Hamburgo, RS, Brazil
[2] Univ Feevale, Inst Hlth Sci, Lab Analyt Toxicol, Novo Hamburgo, RS, Brazil
[3] Hosp Clin Porto Alegre, Oncol Serv, Porto Alegre, RS, Brazil
[4] Univ Fed Ciencias Saude Porto Alegre, Sch Med, Porto Alegre, RS, Brazil
关键词
Dried blood spots; Docetaxel; Therapeutic drug monitoring; LC-MS/MS; CHROMATOGRAPHY/TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN PLASMA; PHARMACOKINETICS; INDIVIDUALIZATION; EXTRACTION; TOXICITY; TAXOTERE; THERAPY; CYP3A;
D O I
10.1016/j.jpba.2018.05.011
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, a LC-MS/MS method for the measurement of docetaxel in Dried Blood Spots (DBS) samples was developed and validated. Docetaxel was extracted from 8 mm DBS punch with a mixture of methanol and acetonitrile (9:1, v/v). The chromatographic separation occurred in an Acquity (R) C18 column (150 x 2.1 mm, 1.7 mu m) eluted with a mixture of water and acetonitrile plus 0.1% formic acid (45:55, v/v). Total analytical run time was 7 min. The method was linear from 50 to 3000 ng ml(-1). Precision assays showed CV% < 9.8% and accuracy between 99 and 103%, mean recovery was 81%. The method was applied in the determination of the docetaxel in 31 patients, after collection of two paired venous blood and DBS samples, following a limited sampling strategy protocol. The analyte was stable in DBS for 18 days at 25 degrees C and 9 days at 45 degrees C. The interval of docetaxel concentrations measured in DBS collected before the end of the infusion was 756-3047 ng ml(-1) and 60 +/- 10 min after the end of the infusion was 57-331 ng ml(-1). AUC values calculated from DBS-derived estimated plasma concentrations (EPC) represented on average 100% of those obtained in plasma samples of 3.1 mgh/l (2.4-4.9 mg h/l). There was a 93% agreement between the classification of patients as within or without the therapeutic range by plasma and EPC AUC. These findings support the clinical use of DBS sampling for routine therapeutic drug monitoring of docetaxel. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:84 / 91
页数:8
相关论文
共 30 条
  • [1] Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods
    Almeida, AM
    Castel-Branco, MM
    Falcao, AC
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02): : 215 - 222
  • [2] Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry
    Andriguetti, Natalia B.
    Hahn, Roberta Z.
    Lizot, Lilian F.
    Raymundo, Suziane
    Costa, Jose L.
    da Cunha, Kelly F.
    Vilela, Ramon M. M.
    Kluck, Helena M.
    Schwartsmann, Gilberto
    Antunes, Marina V.
    Linden, Rafael
    [J]. CLINICAL BIOCHEMISTRY, 2018, 54 : 123 - 130
  • [3] Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
    Andriguetti, Natalia B.
    Raymundo, Suziane
    Antunes, Marina V.
    Perassolo, Magda S.
    Verza, Simone G.
    Suyenaga, Edna S.
    Linden, Rafael
    [J]. CURRENT MEDICINAL CHEMISTRY, 2017, 24 (33) : 3559 - 3582
  • [4] Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes
    Angelini, Silvia
    Botticelli, Andrea
    Onesti, Concetta Elisa
    Giusti, Raffaele
    Sini, Valentina
    Durante, Valeria
    Strigari, Lidia
    Gentile, Giovanna
    Cerbelli, Bruna
    Pellegrini, Patrizia
    Sgroi, Valentina
    Occhipinti, Mario
    Di Pietro, Francesca Romana
    Rossi, Alessandro
    Simmaco, Maurizio
    Mazzuca, Federica
    Marchetti, Paolo
    [J]. ANTICANCER RESEARCH, 2017, 37 (05) : 2633 - 2639
  • [5] [Anonymous], 2001, BIOAN METH VAL
  • [6] Dried blood spots analysis with mass spectrometry: Potentials and pitfalls in therapeutic drug monitoring
    Antunes, Marina Venzon
    Charao, Mariele Feiffer
    Linden, Rafael
    [J]. CLINICAL BIOCHEMISTRY, 2016, 49 (13-14) : 1035 - 1046
  • [7] DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application
    Antunes, Marina Venzon
    Raymundo, Suziane
    Wagner, Sandrine Comparsi
    Mattevi, Vanessa Sune
    Vieira, Natalia
    Leite, Renata
    Reginato, Fabiola
    Capra, Marcelo Zanella
    Fogliatto, Laura
    Linden, Rafael
    [J]. BIOANALYSIS, 2015, 7 (16) : 2105 - 2117
  • [8] Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots-Development, validation and clinical application during breast cancer adjuvant therapy
    Antunes, Marina Venzon
    Raymundo, Suziane
    de Oliveira, Vanessa
    Staudt, Dilana Elisabeth
    Goessling, Gustavo
    Peteffi, Giovana Piva
    Biazus, Jorge Villanova
    Cavalheiro, Jose Antonio
    Tre-Hardy, Marie
    Capron, Arnaud
    Haufroid, Vincent
    Wallemacq, Pierre
    Schwartsmann, Gilberto
    Linden, Rafael
    [J]. TALANTA, 2015, 132 : 775 - 784
  • [9] Baille P, 1997, CLIN CANCER RES, V3, P1535
  • [10] Pharmacogenetic Pathway Analysis of Docetaxel Elimination
    Baker, S. D.
    Verweij, J.
    Cusatis, G. A.
    van Schaik, R. H.
    Marsh, S.
    Orwick, S. J.
    Franke, R. M.
    Hu, S.
    Schuetz, E. G.
    Lamba, V.
    Messersmith, W. A.
    Wolff, A. C.
    Carducci, M. A.
    Sparreboom, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 155 - 163